Deval has more than 20 years of experience helping to build and grow successful companies. He is currently a partner at Telegraph Hill Partner and serves on several boards. Prior to THP he was a founding Research Director at Synteni, which was acquired by Incyte Genomics.
Deval received a BA from the University of California, Berkeley and a PhD from Stanford University and currently serves on the Stanford Medical School Alumni Board of Governors.